The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results